首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1451194

2024-2032 年肝素市场报告（按产品、来源、管理方式、应用、最终用户、配销通路和地区）

Heparin Market Report by Product, Source, Mode of Administration, Application, End-User, Distribution Channel, and Region 2024-2032

出版日期: 2024年03月02日 | 出版商:

IMARC | 英文 148 Pages | 商品交期: 2-3个工作天内

价格

简介目录图表

2023年全球肝素市场规模达73亿美元。展望未来， IMARC Group预计到2032年市场规模将达到89亿美元，2024-2032年复合年增长率（CAGR）为2.2%。心血管疾病有效治疗方案的需求不断增加，慢性病数量大幅增加，需要抗凝血治疗的手术和侵入性手术数量不断增加，以及药物输送系统的不断技术进步是推动市场发展的一些因素。

肝素 (C12H19NO20S3) 是一种广泛使用的抗凝血剂，是一种抑制血液凝固的物质，因此在各种医疗应用中至关重要。这种药物源自于动物组织，用于患者预防静脉、动脉和肺部血栓。肝素主要由硫酸化多醣组成，其特性包括快速起效以及与抗凝血酶 III 形成复合物的能力，使凝血酶失去活性。它可用于各种医疗情况，例如手术、透析以及深部静脉栓塞和肺栓塞的治疗。肝素的作用是增强人体的自然抗凝血反应、分解血栓并防止新血栓的形成。

全球市场的主要驱动力是对心血管疾病有效治疗方案的需求不断增长。与此一致的是，各种价格实惠的肝素选择的广泛使用也为市场提供了动力。此外，老化人口的大幅增加，更容易患凝血障碍，正成为市场成长的重要诱导因素。除此之外，需要抗凝血治疗的手术和侵入性手术数量不断增加，导致产品需求增加。有组织的医疗保健系统的实施进一步推动了市场的发展，该系统需要对血液相关疾病进行适当的管理。除此之外，可能导致凝血障碍的生活方式相关疾病的流行正在推动市场的发展。促进市场发展的其他一些因素包括快速城市化和现代生活方式、向更积极主动的健康管理的文化转变，以及医疗保健提供者、製药公司和研究机构之间的广泛合作。

肝素市场趋势/驱动因素：

慢性病数大幅增加

心臟病、癌症和糖尿病等慢性疾病在全球的上升，使抗凝血剂（尤其是肝素）的使用成为人们关注的焦点。这些慢性疾病通常会导致继发性併发症，例如血块和血栓形成，需要服用抗凝血剂来控制和预防这些潜在的致命事件。随着生活方式的不断发展，久坐习惯、不良饮食和其他因素导致这些慢性疾病的增加，推动了对有效血栓管理治疗的需求。此外，医疗保健从业者和医疗组织正在推广预防措施，包括在高风险患者中使用。这种抗凝血剂在管理日益流行的疾病引起的併发症方面的广泛应用是市场扩张的基石，塑造了医疗保健领域的当前实践和未来趋势。

药物输送系统的持续技术进步

技术创新已成为市场的关键因素。输液帮浦、预充式註射器和标靶输送等药物传递系统的进步确保了抗凝血剂的给药更加准确和有效。这些创新降低了药物过量和副作用的风险，从而提高了患者的安全性和舒适度。此外，随着医疗技术的发展，数位监测与肝素输送的整合可以即时监测患者的反应，从而实现个人化的治疗计划和更大的治疗效果。对这项技术的持续研究和投资不仅改善了抗凝血剂的整体使用体验，而且增强了医疗保健提供者和患者之间的信任。科技和医学在这方面的融合是一个重要的驱动力，引导市场朝着更有活力和以病人为中心的方向发展。

不断增长的监管支持和批准

市场扩张受到监管环境的显着影响，包括各个政府机构、国际组织和医疗机构。严格的监管环境确保肝素产品符合品质、安全性和功效标准。这种审查延伸到从研发阶段到上市后监督的每个阶段。新肝素製剂和应用的快速审批流程，以及明确的指导方针和支持政策，有助于促进药物的可用性和正确使用。此外，监管支持通常延伸到对研究的经济诱因、政府和製药公司之间的合作以及有关血栓疾病的公众宣传活动。透过培育一个平衡安全与创新的环境，监管支持成为肝素市场强劲成长的关键支柱，促进信任，并确保为有需要的患者提供最佳的照护。

市场结构
关键参与者
关键参与者简介
- GlaxoSmithKline Plc
- Shenzhen Hepalink Pharmaceutical Co., Ltd
- Pfizer Inc.
- LEO Pharma A/S
- Sanofi SA
- Dr. Reddy's Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Aspen Holdings
- Baxter International Inc.
- Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
- Sandoz International GmbH
- Opocrin SpA
- Sichuan Deebio Pharmaceutical Co., Ltd.
- Dongying Tiandong Pharmaceutical Co., Ltd.

简介目录图表

Product Code: SR112024A1564

The global heparin market size reached US$ 7.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.9 Billion by 2032, exhibiting a growth rate (CAGR) of 2.2% during 2024-2032. The increasing need for effective treatment options for cardiovascular diseases, considerable rise in the number of chronic conditions, the growing number of surgeries and invasive procedures requiring anticoagulation therapy, and continual technological advancements in drug delivery systems represent some of the factors that are propelling the market.

Heparin (C12H19NO20S3) is a widely used anticoagulant, a substance that inhibits blood clotting, making it essential in various medical applications. Sourced from animal tissues, this medication is administered to patients to prevent blood clots in veins, arteries, and lungs. Comprising mainly of sulfated polysaccharides, the properties of heparin include a rapid onset of action and the ability to form a complex with antithrombin III, which inactivates clotting enzymes. It's used in various medical situations such as during surgeries, dialysis, and in the treatment of deep vein thrombosis and pulmonary embolisms. Heparin works by enhancing the body's natural anticoagulant response, breaking down clots, and preventing the formation of new ones.

The global market is primarily driven by the increasing need for effective treatment options for cardiovascular diseases. In line with this, the widespread availability of varied and affordable heparin options is also providing an impetus to the market. Moreover, the considerable rise in the aging population, more susceptible to clotting disorders, is acting as a significant growth-inducing factor for the market. In addition to this, the growing number of surgeries and invasive procedures requiring anticoagulation therapy is resulting in higher product demand. The market is further driven by the implementation of organized healthcare systems that necessitate the proper management of blood-related conditions. Apart from this, the prevalence of lifestyle-related diseases that may lead to clotting disorders is propelling the market. Some of the other factors contributing to the market include rapid urbanization and modern lifestyles, the cultural shift towards more proactive health management, and extensive collaboration between healthcare providers, pharmaceutical companies, and research institutions.

Heparin Market Trends/Drivers:

Considerable rise in the number of chronic conditions

The global rise in chronic conditions such as heart disease, cancer, and diabetes has brought the use of anticoagulants, particularly heparin, into sharp focus. These chronic conditions often lead to secondary complications like blood clots and thrombosis, requiring the administration of anticoagulants to manage and prevent these potentially fatal occurrences. As lifestyles continue to evolve, sedentary habits, poor diet, and other factors are contributing to an increase in these chronic conditions, thereby pushing the demand for effective clot management treatments. Furthermore, healthcare practitioners and medical organizations are promoting preventive measures, including use in at-risk patients. This wide-ranging applications of this anticoagulant in managing complications from an increasingly prevalent group of diseases is serving as a cornerstone in the expansion of the market, shaping both current practices and future trends in healthcare.

Continual technological advancements in drug delivery systems

Technological innovation has become a pivotal factor in the market. The advancement in drug delivery systems, such as infusion pumps, prefilled syringes, and targeted delivery, ensures that the anticoagulant can be administered more accurately and effectively. These innovations reduce the risk of overdosage and side effects, thereby enhancing patient safety and comfort. Additionally, as medical technology evolves, the integration of digital monitoring with heparin delivery allows for real-time monitoring of patient response, enabling personalized treatment plans and greater therapeutic efficacy. The continuous research and investment in this technology not only improve the overall usage experience of anticoagulants but also foster trust among healthcare providers and patients. The convergence of technology and medicine in this aspect is a significant driving force, steering the market towards a more dynamic and patient-centric direction.

Growing regulatory support and approvals

The market expansion is significantly impacted by the regulatory landscape, encompassing various government bodies, international organizations, and healthcare authorities. The stringent regulatory environment ensures that heparin products meet quality, safety, and efficacy standards. This scrutiny extends to every stage, from the research and development phase to post-market surveillance. Rapid approval processes for new Heparin formulations and applications, alongside clear guidelines and supportive policies, help facilitate the drug's availability and proper usage. Furthermore, the regulatory support often extends to financial incentives for research, collaboration between governments and pharmaceutical companies, and public awareness campaigns about blood clot disorders. By cultivating an environment that balances safety with innovation, the regulatory support serves as a key pillar in the robust growth of the Heparin market, fostering trust, and ensuring that the best possible care reaches patients in need.

Heparin Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global heparin market report, along with forecasts at the global and regional levels from 2024-2032. Our report has categorized the market based on product, source, mode of administration, application, end-user and distribution channel.

Breakup by Product:

Unfractionated Heparin

Low Molecular Weight Heparin (LMWH)

Ultra-Low Molecular Weight Heparin (ULMWH)

Low molecular weight heparin (LMWH) represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the product. This includes unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH). According to the report, low molecular weight heparin (LMWH) represented the largest segment.

The growing preference for low molecular weight heparin (LMWH) can be attributed to its enhanced bioavailability and prolonged action compared to the unfractionated variant. LMWH offers a more predictable dose-response relationship, reducing the need for frequent monitoring and dose adjustments. Its lower risk of causing heparin-induced thrombocytopenia (HIT) contributes to its favorability in both prophylactic and therapeutic settings. Additionally, LMWH's ease of subcutaneous administration and potential for outpatient care further promote its adoption, aligning with the trend towards patient-centric healthcare.

On the other hand, the unfractionated heparin and ultra-low molecular weight heparin (ULMWH) segments of the market are driven by several factors. These factors include their clinical efficacy in preventing and treating thrombotic conditions, their diverse applications in addressing deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis, and the influence of physician preferences based on patient profiles and medical history.

Breakup by Source:

Bovine

Porcine

Porcine accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the source. This includes bovine and porcine. According to the report, porcine represented the largest segment.

The utilization of porcine mucosal tissues as the primary product source is driven by the high concentration of precursors in these tissues. Porcine source remains integral to the heparin production process due to its reliability, scalability, and cost-effectiveness. However, the industry's ongoing exploration of alternative sources, driven by concerns over availability and ethical considerations, underscores the importance of diversifying raw material options to ensure a stable supply chain for this critical anticoagulant.

On the other hand, the use of heparin sourced from bovine origins has been historically prominent in medical applications due to its availability and established track record. Also, continual advances in purification processes have addressed concerns related to potential contaminants and allergenic reactions associated with bovine-sourced anticoagulants, which is impelling the segment.

Breakup by Mode of Administration:

Oral

Parenteral

Oral represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the mode of administration. This includes oral and parenteral. According to the report, oral represented the largest segment.

The development of oral formulations for anticoagulants marks a significant advancement in patient care. The shift from injectable to oral administration stems from the desire to enhance patient compliance, reduce the burden of injections, and facilitate long-term therapy. However, the challenge lies in achieving consistent bioavailability and maintaining predictable anticoagulation effects with oral formulations. Extensive research and clinical trials are being conducted to refine oral anticoagulant drugs, aiming to strike a balance between efficacy, safety, and convenience.

On the other hand, the parenteral mode of administration, involving injections, offers immediate effects that are particularly suitable for acute situations such as stroke and thrombotic events. This mode of administration ensures predictable dosing, which enhances patient safety and treatment efficacy.

Breakup by Application:

Atrial Fibrillation & Heart Attack

Stroke

Deep Vein Thrombosis (DVT)

Pulmonary Embolism (PE)

Others

Atrial fibrillation and heart attacks account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the application. This includes atrial fibrillation & heart attack, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and others. According to the report, atrial fibrillation and heart attacks represented the largest segment.

Atrial fibrillation and heart attacks are pivotal drivers of the demand for various anticoagulants. The increased incidence of these conditions underscores the critical role of timely and effective anticoagulation in preventing thromboembolic events. Atrial fibrillation, characterized by irregular heart rhythms, necessitates ongoing anticoagulant therapy to prevent blood clot formation and potential stroke. Meanwhile, in the context of heart attacks, the product's role as an adjunctive therapy complements other interventions to prevent further clotting and optimize patient outcomes.

On the other hand, the rising prevalence of stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE) drives the demand for effective anticoagulation therapies. The aging global population contributes to a higher incidence of these conditions, emphasizing the need for suitable treatment options.

Breakup by End-User:

Hospitals

Clinics

Homecare Settings

Ambulatory Surgical Centers

Others

Hospitals represent the largest market segment

The report has provided a detailed breakup and analysis of the market based on the end-user. This includes hospitals, clinics, homecare settings, ambulatory surgical centers, and others. According to the report, hospitals represented the largest segment.

Hospitals serve as central hubs for patient care, where the use of heparin spans from surgical procedures to the treatment of thrombotic events for preventing blood clot formation. Hospitals' high patient throughput and critical nature of care emphasize the need for accessible and effective anticoagulation options. As healthcare facilities continue to evolve, optimizing product utilization and management within hospital protocols contributes to patient safety and overall quality of care.

On the other hand, the growing product applications across clinics, homecare settings, and ambulatory surgical centers reflects its versatility in catering to different patient care environments. This is especially convenient for patients, as it allows effective treatment in home-based or ambulatory settings.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Drug Stores

Online Stores

Others

Hospital pharmacies account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, drug stores, online stores, and others. According to the report, hospital pharmacies represented the largest segment.

Hospital pharmacies play a pivotal role in the anticoagulant distribution and management within healthcare institutions. Their efficient procurement, storage, and dispensing of pharmaceuticals impact the product availability for clinicians. Additionally, hospital pharmacies facilitate communication between healthcare providers and manufacturers, ensuring timely restocking and adherence to quality standards. An effectively managed distribution channel contributes to seamless patient care and supports hospital staff in delivering appropriate therapies in a timely manner.

On the other hand, the easy product accessibility in retail pharmacies, drug stores, and online stores ensures wider patient access to necessary anticoagulant medications. This availability caters to diverse consumer preferences, allowing some patients to conveniently obtain anticoagulants from their preferred retail or online sources.

Breakup by Region:

Europe

North America

Asia Pacific

Middle East and Africa

Latin America

North America exhibits a clear dominance, accounting for the largest heparin market share

The report has also provided a comprehensive analysis of all the major regional markets, which include Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share.

The market in the North America region is propelled by the region's high incidence of chronic diseases, notably cardiovascular disorders, deep vein thrombosis, and pulmonary embolism, fuels the demand for heparin as a vital anticoagulant and thromboprophylactic agent.

This demand is further magnified by the increasing proportion of the aging population, a demographic more prone to conditions necessitating anticoagulant treatment. The region's advanced healthcare infrastructure, coupled with the burgeoning number of surgical procedures, including cardiovascular surgeries and orthopedic interventions, fosters a significant need for heparin-based products to mitigate blood clot formation risks.

Improved awareness of thrombotic disorders and enhanced diagnostic techniques contribute to early detection and treatment, amplifying the necessity for product interventions. The stringent regulatory landscape in North America ensures the secure and effective utilization of anticoagulant drugs, including heparin, while ongoing research, collaborative endeavors, and innovations in the field continually refine product efficacy and safety profile. In summation, a dynamic interplay of demographic trends, healthcare infrastructure, medical awareness, regulatory standards, and research advancements collectively stimulate the rising demand for anticoagulant products across various medical domains.

Competitive Landscape:

The leading market players are investing significantly in R&D to develop improved formulations and delivery methods, enhancing the effectiveness and safety of heparin products. These efforts aim to address medical needs more efficiently and reduce potential side effects. To tap into new markets and diversify revenue streams, major manufacturers are expanding their geographic presence by establishing distribution networks, manufacturing facilities, and sales operations in emerging markets. Additionally, they are investing in advanced quality control measures, adherence to Good Manufacturing Practices (GMP), and transparency in their supply chains to maintain customer trust and regulatory approval. The key players are also forming strategic partnerships with research institutions, healthcare providers, and pharmaceutical companies to collectively advance heparin-based treatments.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

GlaxoSmithKline Plc

Shenzhen Hepalink Pharmaceutical Co., Ltd

Pfizer Inc.

LEO Pharma A/S

Sanofi S.A.

Dr. Reddy's Laboratories Ltd.

Teva Pharmaceutical Industries Ltd.

Aspen Holdings

Baxter International Inc.

Hebei Changshan Biochemical Pharmaceutical Co. Ltd.

Sandoz International GmbH

Opocrin S.p.A.

Sichuan Deebio Pharmaceutical Co., Ltd.

Dongying Tiandong Pharmaceutical Co. Ltd.

Recent Developments:

In June 2023, GlaxoSmithKline Plc completed the acquisition of BELLUS, a biopharmaceutical company focusing on refractory chronic cough (RCC) treatment, by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with RCC.

In June 2023, Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. NGENLA is expected to become available for U.S. prescribing in August 2023.

In May 2021, Dr. Reddy's Laboratories Ltd. along with its subsidiaries announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the U.S. Food and Drug Administration (USFDA).

Key Questions Answered in This Report

1. How big is the global heparin market?
2. What is the expected growth rate of the global heparin market during 2024-2032?
3. What are the key factors driving the global heparin market?
4. What has been the impact of COVID-19 on the global heparin market?
5. What is the breakup of the global heparin market based on the product?
6. What is the breakup of the global heparin market based on the source?
7. What is the breakup of the global heparin market based on the mode of administration?
8. What is the breakup of the global heparin market based on the application?
9. What is the breakup of the global heparin market based on the end-user?
10. What is the breakup of the global heparin market based on the distribution channel?
11. What are the key regions in the global heparin market?
12. Who are the key players/companies in the global heparin market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Heparin Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Product
5.5 Market Breakup by Source
5.6 Market Breakup by Mode of Administration
5.7 Market Breakup by Application
5.8 Market Breakup by End-User
5.9 Market Breakup by Distribution Channel
5.10 Market Breakup by Region
5.11 Market Forecast

6 Market Breakup by Product

6.1 Unfractionated Heparin
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Low Molecular Weight Heparin (LMWH)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Ultra-Low Molecular Weight Heparin (ULMWH)
- 6.3.1 Market Trends
- 6.3.2 Market Forecast

7 Market Breakup by Source

7.1 Bovine
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Porcine
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by Mode of Administration

8.1 Oral
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Parenteral
- 8.2.1 Market Trends
- 8.2.2 Market Forecast

9 Market Breakup by Application

9.1 Atrial Fibrillation & Heart Attack
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Stroke
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Deep Vein Thrombosis (DVT)
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
9.4 Pulmonary Embolism (PE)
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
9.5 Others
- 9.5.1 Market Trends
- 9.5.2 Market Forecast

10 Market Breakup by End-User

10.1 Hospitals
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
10.2 Clinics
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
10.3 Homecare Settings
- 10.3.1 Market Trends
- 10.3.2 Market Forecast
10.4 Ambulatory Surgical Centers
- 10.4.1 Market Trends
- 10.4.2 Market Forecast
10.5 Others
- 10.5.1 Market Trends
- 10.5.2 Market Forecast

11 Market Breakup by Distribution Channel

11.1 Hospital Pharmacies
- 11.1.1 Market Trends
- 11.1.2 Market Forecast
11.2 Retail Pharmacies
- 11.2.1 Market Trends
- 11.2.2 Market Forecast
11.3 Drug Stores
- 11.3.1 Market Trends
- 11.3.2 Market Forecast
11.4 Online Stores
- 11.4.1 Market Trends
- 11.4.2 Market Forecast
11.5 Others
- 11.5.1 Market Trends
- 11.5.2 Market Forecast

12 Market Breakup by Region

12.1 Europe
- 12.1.1 Market Trends
- 12.1.2 Market Forecast
12.2 North America
- 12.2.1 Market Trends
- 12.2.2 Market Forecast
12.3 Asia Pacific
- 12.3.1 Market Trends
- 12.3.2 Market Forecast
12.4 Middle East and Africa
- 12.4.1 Market Trends
- 12.4.2 Market Forecast
12.5 Latin America
- 12.5.1 Market Trends
- 12.5.2 Market Forecast

13 SWOT Analysis

13.1 Overview
13.2 Strengths
13.3 Weaknesses
13.4 Opportunities
13.5 Threats

14 Value Chain Analysis

15 Porter's Five Forces Analysis

15.1 Overview
15.2 Bargaining Power of Buyers
15.3 Bargaining Power of Suppliers
15.4 Degree of Competition
15.5 Threat of New Entrants
15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

17.1 Market Structure
17.2 Key Players
17.3 Profiles of Key Players
- 17.3.1 GlaxoSmithKline Plc
- 17.3.2 Shenzhen Hepalink Pharmaceutical Co., Ltd
- 17.3.3 Pfizer Inc.
- 17.3.4 LEO Pharma A/S
- 17.3.5 Sanofi S.A.
- 17.3.6 Dr. Reddy's Laboratories Ltd.
- 17.3.7 Teva Pharmaceutical Industries Ltd.
- 17.3.8 Aspen Holdings
- 17.3.9 Baxter International Inc.
- 17.3.10 Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
- 17.3.11 Sandoz International GmbH
- 17.3.12 Opocrin S.p.A.
- 17.3.13 Sichuan Deebio Pharmaceutical Co., Ltd.
- 17.3.14 Dongying Tiandong Pharmaceutical Co., Ltd.

简介目录图表

List of Figures

Figure 1: Global: Heparin Market: Major Drivers and Challenges
Figure 2: Global: Heparin Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Heparin Market: Breakup by Product (in %), 2023
Figure 4: Global: Heparin Market: Breakup by Source (in %), 2023
Figure 5: Global: Heparin Market: Breakup by Mode of Administration (in %), 2023
Figure 6: Global: Heparin Market: Breakup by Application (in %), 2023
Figure 7: Global: Heparin Market: Breakup by End-User (in %), 2023
Figure 8: Global: Heparin Market: Breakup by Distribution Channel (in %), 2023
Figure 9: Global: Heparin Market: Breakup by Region (in %), 2023
Figure 10: Global: Heparin Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 11: Global: Heparin Industry: SWOT Analysis
Figure 12: Global: Heparin Industry: Value Chain Analysis
Figure 13: Global: Heparin Industry: Porter's Five Forces Analysis
Figure 14: Global: Heparin (Unfractionated) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Heparin (Unfractionated) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Heparin (Low Molecular Weight) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Heparin (Low Molecular Weight) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Heparin (Ultra-Low Molecular Weight) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Heparin (Ultra-Low Molecular Weight) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Heparin (Bovine) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Heparin (Bovine) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Heparin (Porcine) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Heparin (Porcine) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Heparin (Oral) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Heparin (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Heparin (Parenteral) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Heparin (Parenteral) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Heparin (Atrial Fibrillation & Heart Attack) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Heparin (Atrial Fibrillation & Heart Attack) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Heparin (Stroke) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Heparin (Stroke) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Global: Heparin (Deep Vein Thrombosis) Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Global: Heparin (Deep Vein Thrombosis) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Global: Heparin (Pulmonary Embolism) Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Global: Heparin (Pulmonary Embolism) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Global: Heparin (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Global: Heparin (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Global: Heparin (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Global: Heparin (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Global: Heparin (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Global: Heparin (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Global: Heparin (Homecare Settings) Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Global: Heparin (Homecare Settings) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Global: Heparin (Ambulatory Surgical Centers) Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Global: Heparin (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Global: Heparin (Other End-Users) Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Global: Heparin (Other End-Users) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Global: Heparin Market: Sales through Hospital Pharmacies (in Million US$), 2018 & 2023
Figure 49: Global: Heparin Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2024-2032
Figure 50: Global: Heparin Market: Sales through Retail Pharmacies (in Million US$), 2018 & 2023
Figure 51: Global: Heparin Market Forecast: Sales through Retail Pharmacies (in Million US$), 2024-2032
Figure 52: Global: Heparin Market: Sales through Drug Stores (in Million US$), 2018 & 2023
Figure 53: Global: Heparin Market Forecast: Sales through Drug Stores (in Million US$), 2024-2032
Figure 54: Global: Heparin Market: Sales through Online Stores (in Million US$), 2018 & 2023
Figure 55: Global: Heparin Market Forecast: Sales through Online Stores (in Million US$), 2024-2032
Figure 56: Global: Heparin Market: Sales through Other Distribution Channels (in Million US$), 2018 & 2023
Figure 57: Global: Heparin Market Forecast: Sales through Other Distribution Channels (in Million US$), 2024-2032
Figure 58: Europe: Heparin Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Europe: Heparin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: North America: Heparin Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: North America: Heparin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Asia Pacific: Heparin Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Asia Pacific: Heparin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Middle East and Africa: Heparin Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Middle East and Africa: Heparin Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Latin America: Heparin Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Latin America: Heparin Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

Table 1: Global: Heparin Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Heparin Market Forecast: Breakup by Product (in Million US$), 2024-2032
Table 3: Global: Heparin Market Forecast: Breakup by Source (in Million US$), 2024-2032
Table 4: Global: Heparin Market Forecast: Breakup by Mode of Administration (in Million US$), 2024-2032
Table 5: Global: Heparin Market Forecast: Breakup by Application (in Million US$), 2024-2032
Table 6: Global: Heparin Market Forecast: Breakup by End-User (in Million US$), 2024-2032
Table 7: Global: Heparin Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 8: Global: Heparin Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 9: Global: Heparin Market Structure
Table 10: Global: Heparin Market: Key Players

02-2729-4219

+886-2-2729-4219